114 results on '"Kapiteijn E"'
Search Results
2. 791MO Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma
3. 859P The influence of hematologic malignancies on response to immune checkpoint inhibition in patients with advanced melanoma
4. 832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM)
5. 812P Early experiences in adjuvant treatment of melanoma: Real-world data on tolerability, safety and efficacy
6. 860P The IOpener study: Tyrosine kinase activity in peripheral lymphocytes to predict durable response to immune checkpoint inhibition in patients with advanced melanoma
7. 115P Gene rearrangements, actionability and access to precision medicine: Results from the ARCAGEN study
8. LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial
9. 1140TiP Safe stop IPI-NIVO trial: Early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
10. 23P A comprehensive analysis of the mucosal melanoma immune microenvironment
11. 1499P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab: Week 60 update of the PRADO trial
12. 1018P Characterization of liver function tests following tebentafusp in phase III randomized trial comparing tebentafusp with investigator’s choice in first line metastatic uveal melanoma (mUM)
13. 1750P Molecular genotyping in refractory thyroid cancers: Results of a European survey
14. 1081P Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nation-wide quality assurance in the Netherlands
15. 1070P Adjuvant treatment for melanoma in clinical practice: Trial versus reality
16. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial†
17. 132MO Molecular profiling of 991 prospectively recruited rare cancers patients in EUROPE: First results of ARCAGEN – an EORTC-SPECTA and EURACAN study
18. 1153P Incidence and characteristics of immunotherapy related adrenal insufficiency in a monocenter, pan-cancer cohort of 4314 patients
19. 1157P Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival
20. 1128P A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma
21. 1123P Baseline tumor-infiltrating lymphocytes and response to immune checkpoint inhibition in advanced melanoma
22. 1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
23. 1092P Adjuvant treatment with anti-PD-1 in acral melanoma patients: A nationwide study
24. 37P First-line BRAF/MEK-inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: A propensity-matched survival analysis
25. New treatment modalities in advanced thyroid cancer
26. 1080MO The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition
27. 1085P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only versus therapeutic lymph node dissection: 24-week results of the PRADO trial
28. 1120P Post-approval trials versus patient registries: Comparability of advanced melanoma patients with brain metastases
29. 1919P Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: A multicenter EORTC prospective randomized double-blind phase II study (NCT01788982)
30. 1103P Long-term survival of real-world advanced melanoma patients treated with targeted therapy
31. 1200P Tyrosine kinase activity profiling as a predictive biomarker for clinical benefit to immune checkpoint inhibition in advanced melanoma and NSCLC
32. 1130P BRAF and MEK inhibition in CDKN2A germline carriers and BRAF mutant melanoma
33. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome
34. Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
35. ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
36. Health-related quality of life of advanced melanoma survivors treated with CTLA-4 immune checkpoint inhibition: A matched cohort study
37. Successful use of interferon-alpha and adoptive T cell therapy for metastatic melanoma patients failing other treatment options
38. A noninferiority trial of cabozantinib (C) comparing 60 mg vs 140 mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC)
39. Outcomes of anti-PD1 antibodies for advanced melanoma in real-world population
40. ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma
41. Late physical, psychological and social consequences of ipilimumab treatment in advanced melanoma
42. Combined radiofrequency ablation and ipilimumab in uveal melanoma: Results from the SECIRA-UM trial
43. 1621P - Health-related quality of life of advanced melanoma survivors treated with CTLA-4 immune checkpoint inhibition: A matched cohort study
44. 1373TiP - ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
45. 1353P - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
46. 32O - Successful use of interferon-alpha and adoptive T cell therapy for metastatic melanoma patients failing other treatment options
47. Survival in BRAF-mutant metastatic melanoma in the real-world setting: results from the Dutch Melanoma Treatment Registry
48. The influence of old age on everolimus exposure in patients with cancer
49. Real-world survival results of metastatic melanoma patients treated with ipilimumab in the Netherlands
50. 1829TiP - A noninferiority trial of cabozantinib (C) comparing 60 mg vs 140 mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.